New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease - Seite 2
Title:
Impact of Percepta Bronchial Genomic Classifier on Lung Nodule Management at an Academic Medical Center
Abstract #:
39994 (oral presentation)
Presenter:
Harpreet Singh, M.D., Medical College of Wisconsin
Date/Time:
Monday, October 18, 12:15 p.m.-1:20 p.m. CT
Title:
The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Interstitial Lung Disease
Abstract #:
40063 (oral presentation)
Presenter:
Joseph Lasky, M.D., Tulane University Medical School
Date/Time:
On-Demand October 17-21
Title:
Role of Next Generation Sequencing with Percepta Brushing in Reclassifying Lung Nodule Risk After Non-Diagnostic Bronchoscopy
Abstract #:
36774 (poster)
Presenter:
Abhijit Raval, M.D., AnMed Health Medical Center
About Veracyte
Lesen Sie auch
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).